Aminatidi;334659 wrote:What's the view on this?
https://www.vanguardinve...ulation-shares/overview
Holding Name % of funds
Merck & Co Inc 1.99%
Johnson & Johnson 1.97%
Bank of America Corp 1.87%
Philip Morris International Inc 1.76%
FinecoBank Banca Fineco SpA 1.73%
Novartis AG 1.73%
AstraZeneca PLC 1.71%
TotalEnergies SE 1.68%
Cisco Systems Inc 1.62%
Deere & Co 1.56%
Good = low fees
Bad = consistently poor performance historically
But who knows how it will perform in future.
Using their own data from the link shared, their performance vs the benchmark they've chosen;
2017 = -0.6%
2018 = -3.12%
2019 = -8.18%
2020 = -13.66%
2021 = -0.93%
2022 = +17.81%
2023 = -11.53%
2024 = -6.52%
That's 7 misses out of 8 attempts.
We can't rebuy 2022's performance unfortunately.
Now performance vs a benchmark of course isn't the be all and end all. These days I honestly don't have an issue with a fund that doesn't beat a benchmark if it does something else for me.
For example if it has lower drawdowns and lower volatility, I can understand swapping some returns for that defensiveness. In fact I'm all for that - I prefer active funds that play defence rather than try to "outperform".
But this one has been more volatile with bigger drawdowns too.
So I'd basically be paying them to give me more volatility, bigger drawdowns and to underperform against the benchmark.